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ABSTRACT
Alternative splicing (AS) is a robust generator of
mammalian transcriptome complexity. Splice site
specification is controlled by interactions of cis-
acting determinants on a transcript with specific
RNA binding proteins. These interactions are fre-
quently localized to the intronic U-rich polypyrimi-
dine tracts (PPT) located 5′ to the majority of splice
acceptor junctions. CPs (also referred to as polyC-
binding proteins (PCBPs) and hnRNPEs) comprise a
subset of KH-domain proteins with high affinity and
specificity for C-rich polypyrimidine motifs. Here, we
demonstrate that CPs promote the splicing of a de-
fined subset of cassette exons via binding to a C-
rich subset of polypyrimidine tracts located 5′ to the
CP-enhanced exonic segments. This enhancement
of splice acceptor activity is linked to interactions of
CPs with the U2 snRNP complex and may be medi-
ated by cooperative interactions with the canonical
polypyrimidine tract binding protein, U2AF65. Analy-
sis of CP-targeted exons predicts a substantial im-
pact on fundamental cell functions. These findings
lead us to conclude that the CPs play a direct and
global role in modulating the splicing activity and in-
clusion of an array of cassette exons, thus driving
a novel pathway of splice site regulation within the
mammalian transcriptome.
INTRODUCTION
RNA splicing is a highly dynamic process that involves as
many as 200 protein factors interactingwith target sites on a
PolII transcript. While many of these RNA-protein (RNP)
interactions have been described in detail, the broad array
of alternative splicing (AS) events detected in mammalian
cells (1,2) and the large number of RNA binding proteins
(RBPs) encoded by the mammalian genome, suggest that
numerous additional determinants of splicing controls re-
main to be identified and characterized (3–7). Many of the
relevant RBPs (at least 141) compose core components of
the mammalian spliceosome complexes (3,8–10) that inter-
act with splice donor and splice acceptor regions and cat-
alyze intron excision and exon ligation (8). The ‘strength’ of
a splice acceptor site is impacted by the assembly of RNP
complexes at a polypyrimidine tract (PPT) located imme-
diately 5′ of the AG splicing acceptor site. This PPT char-
acteristically consists of a loosely defined U-rich sequence
with interspersed C residues (8,11–14). The splicing factor
U2AF65 binds directly to this U-rich PPT and recruits its
heterodimeric partner U2AF35 and the U2 snRNP com-
plex to the splicing branch site with the initiation of the first
of two trans-esterification reactions (8).
Control of splice acceptor activity can be mediated by
altering the efficiency and/or productivity of the interac-
tions between U2AF65 and the PPT (8). For example, the
RNA binding proteins PTB and hnRNPC have been pro-
posed to repress splice acceptor utilization by blocking the
binding and/or activity of U2AF65 at the PPT (11,14,15).
The mechanistic details of repression by these two fac-
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tors appear to be distinct and remain to be fully defined
(11,14,15). Recent studies indicate that RBFOX2 protein
regulates binding of the early intron recognition factors
U2AF and theU1 small nuclear ribonucleoprotein complex
(snRNP) (16). Additional sets of RNAbinding proteins fur-
ther contribute to activating or repressing controls over AS.
Many of these proteins may be widely expressed while oth-
ers may mediate regulation of splicing programs in specific
cell types (e.g. ESRP family and Nova family (17–21)).
The CP proteins (also referred to as polyC-binding pro-
teins (PCBPs) and hnRNPEs) comprise a family of RBPs
encoded at four dispersed loci (22). These widely expressed
proteins contain three highly conserved RNA binding KH
domains and shuttle between the nucleus and the cytoplasm
(23). The twomost highly expressed of these proteins, CP1
and CP2, are present in all metazoan organisms studied to
date. CPs have been demonstrated to regulate mRNA sta-
bility (24–26) and translation (27,28) in the cytoplasm and
exert a global impact on 3′ processing of transcripts in the
nucleus (29,30). Several studies have reported an additional
impact of CPs on splicing of specific transcripts encoding
CD44 (31–33), Tau (34), CD45 (35) and human (h)-globin
(36,37).
In the current study, we define a global impact of CPs
on alternative splicing. The data reveal that the CPs selec-
tively enhance the splicing (inclusion) of a defined subset of
cassette exons in the human transcriptome. These cassette
exons targeted by CPs are characterized by a cytosine-rich
subset of PPTs adjacent to their splice acceptor sites. The
demonstrated interactions of CPs with U2 spliceosome-
associated proteins and with U2AF65 are likely to support
their observed splicing functions. These findings lead us to
conclude that CP interactions with C-rich PPTs play a sig-
nificant role in the AS of a subset of cassette exons.
MATERIALS AND METHODS
Cell culture and siRNA/shRNA transfection
K562 cells were cultured in RPMI 1640 medium, sup-
plemented with 10% fetal bovine serum (FBS) (HyClone)
and antibiotic/antimycotic at 37◦C in a 5% CO2 incu-
bator. K562 cells were transfected with CP siRNAs
or shRNAs using Nucleofector V (Amaxa) as previ-
ously described (30). The two CP1/2 co-depletion siR-
NAs are previously reported (30). siRNAs to U2AF65
(HSS117616, HSS117617, HSS117618); siRNAs to CP1
(HSS107632, HSS107633, HSS107634); siRNAs to CP2
siRNAs (HSS143239, HSS143241, HSS181787) and nega-
tive control siRNA (medium GC content) were purchased
from Invitrogen. The CP(1/2)-2 siRNA (30), which tar-
gets the 3′ UTR of native CP1/2 mRNA, was converted
to shRNA based on pGFP-V-RS parental vector (Ori-
gene Technologies, Inc.). These shRNAswas co-transfected
along with scrambled control shRNAs in a subset of stud-
ies (Figures 3C and D, and 4B). The siRNA sequences for
Figure 1B are shown in Table 3.
RNA-seq analysis
RNA-seq libraries were constructed using the TruSeq RNA
Sample Preparation Kit V1 according to manufacturer’s in-
struction. The libraries corresponded to the three control
siRNA depletions and three CP1/2 co-depletions. These
six samples comprised four samples used and validated in
our previous analysis of 3′ processing (Figure 1, Ji, 2013
MCB (30)) and additional two siRNA treated K562 sam-
ples, one control siRNA (CTRL-3: non-targetting, Dhar-
macon, Inc) and one CP1/2 siRNA(CP1/2–3, same as
(CP1/2–1 in (30)) (Figure 1B). These libraries were mul-
tiplexed and sequenced on a single channel on the Hiseq-
2000 platform using a 100 nt paired-end sequencing proto-
col by NGSC at University of Pennsylvania (https://ngsc.
med.upenn.edu/).
Alternative splicing analysis
RNA-seq reads were mapped to the human transcriptome
(Ensembl, release 65) and genome (hg19) using the soft-
ware Tophat (38) (v1.4.1) allowing up to 3 bp mismatches
per read and up to 2 bp mismatches per 25 bp seed. CP-
regulated differential AS events corresponding to five ma-
jor types of AS patterns were identified by rMATS (v3.0.7)
(39,40) (http://rnaseq-mats.sourceforge.net/) (Table 1). For
each AS event, both the reads mapped to the exon–exon
junction and the reads mapped to the exon body were used
as rMATS input. Putative CP-regulated AS events were
identified as those with significant difference in inclusion
levels (|PSI|≥5%) between knockdown and control at an
FDR < 5%.
Motif enrichment analysis
Motifs that were significantly enriched in differential exon
skipping events between the CP depleted and control sam-
ples were identified by comparison to background (non-
regulated) alternative exons. A total of 4527 alternative ex-
ons without splicing changes (rMATS FDR > 50%) in
highly expressed genes (FPKM > 5.0 in at least one sam-
ple group) were treated as a background exon set. RNA-
seq based gene expression levels (FPKM) were calculated
by Cuffdiff (v2.2.0) (41). A MEME analysis (v4.9.0) was
carried out to detect enriched motifs in a 500 bp window
centered on the splice acceptor and splice donor sites (42).
To examine the enrichment of identified motifs in the vicin-
ity of the CP regulated exons, the 500 bp windows were
analyzed as 50 bp bins with step-size of 1 bp and the occur-
rence of each motif within each bin was assessed for posi-
tional distribution of each motif.
Ingenuity pathway analysis
The enrichment analyses of biological functions were gen-
erated through the standard use of the IPA package
(Ingenuity R© Systems). Using the Ingenuity Knowledge
Base as a reference set, this analysis identified the most sig-
nificant biological functions associated with the set of genes
that showed significant changes in exon inclusion following
CP depletion. Right-tailed Fisher’s exact test was used to
calculate the P-values determining the probability of each
function assigned to the tested data set is due to chance
alone.
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Table 1. CP1/2 co-depletion impacts on splicing of a subset of exons
(A) Alternative splicing events: CP KD. versus CTRL (rMATS 3.0.7, hg19, Ensembl release 65 GTF)
AS events Significant events FDR <5%, |PSI| ≥ 5%
SE (Skipped exon) 1051
MXE (mutually exclusive exon) 168
A5SS (Alternative 5′ splice site) 56
A3SS (Alternative 3′ splice site) 85
RI (Retained intron) 191
Total 1551
(B) Distributions of C-rich motifs flanking CP1/2 enhanced cassette exons (749)
C-rich motif 3′ of exon
(+) (−)
5′ of exon (+) 311 333
(−) 42 63
(A) Five categories of AS impacted by CP1/2 co-depletion are determined by MATS analysis of RNA-seq data sets. The numbers of AS events impacted
either positively or negatively by CP1/2 depletion are summarized for each of the 5 categories. These data were accrued by rMATS analysis at the indicated
PSI as described (Materials andMethods). (B) Distributions of C-rich motifs flanking 749 cassette exons (Skipped exon) whose inclusion was depressed
in CP1/2 co-depleted cells.
Table 2. Ingenuity pathway analysis of genes with significant changes (positive or negative) in exon inclusion subsequent to CP depletion
(A) Ingenuity pathway analysis of genes with significant exon inclusion level change (enhanced or inhibited) subsequent to CP depletion
Molecular and cellular functions P-value Number of genes
Cell death and survival 9.62E-03 - 2.08E-11 292
Gene expression 7.71E-04 - 6.46E-11 201
Cellular growth and proliferation 1.00E-02 - 1.41E-10 290
Cell cycle 9.77E-03 - 3.74E-07 139
RNA post-transcriptional modification 2.71E-03 - 1.13E-05 35
(B) Ingenuity pathway analysis of genes from 644 cassette exons with 5′ PPT C-rich motif whose inclusion is enhanced by CPs
Molecular and cellular functions P-value Number of genes
Cell death and survival 2.19E-02 - 3.45E-07 157
Cell cycle 2.19E-02 - 1.04E-05 53
Gene expression 2.19E-02 - 2.21E-05 100
Cellular assembly and organization 2.19E-02 - 2.99E-05 111
Cell morphology 2.19E-02 - 3.47E-05 104
(A) Ingenuity pathway analysis of genes with significant exon inclusion level change (enhanced or inhibited) subsequent to CP depletion. (B) Ingenuity
pathway analysis of genes from 644 cassette exons with 5′ PPT C-rich motif. A total of 333 of the cassette exons whose inclusion is enhanced by CP1/2
contain the C-rich solely upstream position and 311 contain the C-rich motif both upstream and downstream of the target exon.
Table 3. Primers used in the RT-PCR validation studies. Refer to Material and Methods for siRNAs and primers not included in this table
Gene name for
RT-PCR Forward/Reverse primer sequence
VKORC1 CTTTGCCTGACGGGCTTAGT / CCAGGTAGACAGAACCAGCG
WNK4 GCTGCGTAAAGCAAGGGAAT / ACGTGGAATGGATAGGGCAA
ARHGAP4 TGGATCCTCCAGGGGACAAA / AATCAAGCACATCCCCGTCA
Stat2 TGCTCTCAGTTGGCAGTTCT / ATGGTAACTTGCCAGGAGGG
AP1G2 AGCTGGCCAAACTGCTCTAC / GTGCTCAAAGTGCACAAGGC
Human CDK2 GCTTTTGGAGTCCCTGTTCG / GGTCCCCAGAGTCCGAAAGA
TARS2 CCAACTGCCCCTGAGATTTG / TCTTTGGCGTATTCCTCTTGCT
SH2B1 CACCCCATCCCTTTGGAGTC / GTCCATGAAGGGGGTTCAGG
TRPT1 GCATGCGGTCCCATTGTGAA / GCTTGGGGCTACTCTGACAC
TFR2 AGCGGCTTTGGGGTCTATTC / TAGAGTCTGCCCTGGTGGAA
CTTN TGGTGTGCAGACAGACAGAC / CCATACTTCCCGCCGAATCC
siRNA for CPs
(Figure 1B)
sequence
CP1/2-3 GUG AAA GGC UAU UGG GCA A
CTRL-3 siGENOME Non-Targeting siRNA #2, Dharmacon, Inc
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Figure 1. Co-depletion of CP1/2 in K562 cells enhances splicing of a subset of cassette exons that are enriched for C-rich splice junctions. (A) Assessing
the impact of CP1/2 co-depletion on cassette exon splicing; work-flow schematic. Three pools of K562 cells were co-depleted of CP1 and CP2 via
transfection with siRNAs that co-target both encoding mRNAs (CP1/2 siRNA). Three cell pools transfected with control siRNAs served as parallel
controls (seeMaterials andMethods). Three days post-transfection CP1/2 depletion was confirmed at the levels of mRNA and protein and the transcrip-
tomes from the depleted and control cell pools were analyzed by RNA-seq. RNA-seq data in these control and CP1/2 co-depleted transcriptomes were
compared by informatic approaches to detect alterations in transcript splicing (see text). (B) Co-depletion of CP1 and CP2 proteins from K562 cells.
K562 cells were transfected with siRNA CP(1/2)-3 co-targeting CP1 and CP2 or with scrambled sequence control siRNA (CTRL-3). Three days post
transfection the cells were harvested and assayed by Western blot with antibodies specific to CP1 and CP2. Gel loading was assessed using an antibody
to ribosomal protein L7a (45). (C) Motif analysis of cassette exons whose inclusion was impacted in CP1/2 co-depleted cells. Cassette exons impacted
in cells co-depleted of CP1/2 were identified by comparative RNA-seq (Table 1). The regions 250 bases ‘upstream’ or ‘downstream’ of each impacted
cassette exon in each of the two categories was assessed by MEME (v4.9.0) for conserved motifs. The level of significance was determined by comparison
to a ‘Background’ set of 4527 non-impacted alternative exons (rMATS FDR > 50%) in highly expressed genes (FPKM > 5.0). A C-rich motif (shown in
the inset) was specifically identified flanking the CP1/2-enhanced exons (i.e. those repressed by CP1/2 co-depletion) in contrast to exons repressed or
unaffected (Background). The graph shows the positional distribution of this C-rich motif across the regions 5′ and 3′ to the cassette exon (green rectangle).
The analysis was executed on 50 bp bins across the indicated regions in each of the three exon groups (CP1/2-enhanced, CP1/2-repressed, background).
(D) Motif analysis of exons whose inclusion was not impacted in CP1/2 co-depleted cells. Analysis as in (C). The graph shows the positional distribution
of the identified U-rich MEME consensus motif (shown in the insert) as assessed by analysis of 50 bp bins across the indicated regions in each of the three
exon groups (CP1/2-enhanced, CP1/2-repressed, background).
Accession number
All RNA-seq data were deposited to the NCBI Gene
Expression Omnibus (43) under the accession number
GSE71569. The U2AF65 eCLIP data set of the K562
cell line was downloaded from the ENCODE data portal
(https://www.encodeproject.org/) with the accession num-
ber ENCSR893RAV.
U2AF65 eCLIP data and motif analysis
U2AF65 ‘enhanced’ CLIP (eCLIP) data of the K562 cell
line was downloaded from the ENCODEdata portal (https:
//www.encodeproject.org/). Before mapping to the tran-
scriptome, the eCLIP reads were processed using the fastx-
toolkit. Adapter sequences were trimmed by fastx clipper
and low quality reads were filtered using fastq quality filter.
This analysis required at least 50% of any given read to have
a quality score over 30. PCR duplicates were removed by
collapsing all the reads (fastx collapser) and random bar-
codes were removed. Reads were then mapped using the
novoalign software (Novocraft, http://www.novocraft.com)
with peak calling executed using Piranha (44).
To obtain the eCLIP read density along different groups
of exons, we first obtained the intersection between the
eCLIP peaks and 100 nucleotide long regions upstream and
downstream of the three groups of exons (CPs-enhanced,
CPs-repressed and background groups). The coverage was
calculated for each nucleotide in the resulting genomic re-
gions (i.e. 100 nucleotide regions 5′ and 3′ of the three
groups of exons that have eCLIP peaks). The coverage value
represents the number of reads that cover each nucleotide.
In order to center the coverage distribution at the presumed
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eCLIP crosslink site and to avoid the read length shift in
the coverage distribution, the eCLIP reads were shifted to
center the reads at the presumed crosslink site. The cov-
erage count was normalized to the maximum coverage in
each transcript to control for transcript expression levels
and avoid having highly expressed transcripts dominate the
signal. After this normalization step the coverage for each
nucleotide position in a given transcript was represented
as a number between 0 and 1. Averaging the correspond-
ing value for each nucleotide position in all the exons and
plotting the density curve yielded the distribution of eCLIP
reads upstream and downstream of the exon splice acceptor
site. The U2AF65 motif scores were calculated by count-
ing all the instances of the U2AF65 motif (TTTTT [C/T]T;
as defined by the RNAcompete assay in (12)) in a sliding
window of 25 nucleotides in a 100 nucleotide region up- or
down-stream of the three groups of exons. When sliding the
window by one nucleotide at a time, the motif score was cal-
culated with the following formula:
Motif score for a given region =
# of unique nucleotides covered by the motif
# of nuceotide in the window
Co-Immunoprecipitation (co-IP) and Western blot analysis
K562 cells were washed with ice-cold phosphate buffered
saline (PBS) twice and lysed in 1000 l of ice-cold ly-
sis buffer (50 mM HEPES [pH 7.4], 150 mM NaCl, 1
mM EDTA, 10% glycerol, 1% Triton-X-100, 100 g/ml
RNase A and protease inhibitor) for 30 min at 4◦C with
rotation. The lysates were centrifuged at 10 000 g for 10
min, and the supernatant was collected and used for im-
munoprecipitation (IP). IP was carried out as described
previously (45) with magnetic beads (Novex). IP pellets
were dissolved in SDS-loading buffer and were separated
on NuPAGE gel and electroblotted to nitrocellulose mem-
branes (Protran BA 85; Schleicher & Schuell) for 1 h at
150 mA in transfer buffer (20 mM Tris, 150 mM glycine,
20%methanol) using a Semi-phor transfer apparatus (Hoe-
fer). The membranes were blocked in 3% nonfat milk in
1x PBS for 1 h at room temperature, followed by an ad-
ditional hour with primary antisera. Primary rabbit anti-
body to SF3b145 (A301–605A) was purchased fromBethyl.
Anti-U2AF65 antibody, a mouse monoclonal (U4758), was
purchased from Sigma. HRP-labeled secondary antibodies
(Amersham) were used as detailed by the supplier. Don-
key anti-rabbit immunoglobulin G (IgG)-horseradish per-
oxidase and sheep anti-mouse immunoglobulin G (IgG)-
horseradish peroxidase (HRP) secondary antibodies were
used at a 1:5000 dilution (Amersham) and signals were vi-
sualized by ECL (ECL reagents; Boehringer Mannheim).
For quantitative analysis, the primary antibody was vi-
sualized with a fluorophore conjugated secondary anti-
body (IRDye800CW anti-rabbit, #925–32213, LI-COR,
Lincoln, NE) and the signal density was measured on a
LI263 COR Odyssey CLx Imaging platform.
The IP study quantifying the association with U2A65
with the WT and Mut-2 TARS2 exon 14 (Figure 4D)
was carried out on a single-intron minigene constructs (see
Minigene analysis, below). Each indicated minigene was in-
dividually transfected into K562 cells and corresponding
cell extracts were isolated one day post-transfection. IPs
with antibodies to U2AF65 (U4758, Sigma) bound to mag-
netic beads (Novex) were carried out as described previ-
ously (45). Pre-immune serum (P.I.) was used as IP con-
trol. U2AF65 occupancy at the single splice acceptor in the
single exon minigene was quantified by RT-PCR of the co-
IP’edRNA.RT-PCRofGAPDHmRNAwas used as back-
ground control. The ratio of TARS2/GAPDH was calcu-
lated with the WT defined as 1.0.
EMSA
RNA oligonucleotides were synthesized and 5′-end labeled
using T4 polynucleotide kinase (NEB, Beverly, MA, USA)
and [ -32P]ATP (Amersham). All labeled oligonucleotides
were gel purified on 12% denaturing gels prior to use. Elec-
trophoretic mobility shift assays (EMSA) were carried out
as described previously (24) withminormodifications. A to-
tal of 5 ng of each probe (∼20 000 cpm) was mixed with
30 g of K562 S100 extract, The incubation was in 20 l
of binding buffer (10 mM Tris-HCl [pH 7.4], 150 mMKCl,
1.5 mMMgCl2 and 0.5 mMdithiothreitol) at room temper-
ature for 20 min. One microliter of heparin (50 mg/ml) was
added to each reaction mixture for 10 min prior to loading.
Samples were resolved on a non-denaturing 5% polyacry-
lamide gel.
RT-PCR
RNAs were treated with DNase I (Invitrogen) and then re-
verse transcribed using oligo-dT,Moloneymurine leukemia
virus reverse transcriptase (Promega), and 1x Moloney
murine leukemia virus reverse transcription (RT) buffer
(Promega) according to manufacturer’s instruction. After
incubation at 37◦C for 1 h, the samples were used as a tem-
plate for PCR. The forward primer (20 pmol) was end la-
beled by incubation with [ 32 P]ATP. The PCRs included 1
l of the RT product, 0.2 mM dNTPs, 1.5 mM MgCl2, 1
pmol of the labeled primer, 20 pmol of each primer, 0.25 U
of AmpliTaq (Perkin Elmer) and 1x PCR buffer II (Perkin
Elmer) in a 25-l reaction. The number of PCR cycles in
each study was adjusted to the primers used and originating
RNA concentrations. Samples were visualized by 6% dena-
ture polyacrylamide gel electrophoresis (PAGE) and quan-
tified by the PhosphorImager (ImageQuant;Molecular Dy-
namics). Alternative splicing efficiency was determined by
calculating the inclusion level (%) of the cassette exon in all
isoforms. RT-PCR primers are listed in Table 3 and others
from a recent report (13).
Minigene analysis of alternative 5′ and 3′ splice sites
WT and mutant TARS2 minigenes were cloned into the pI-
11(-H3)-PL adenovirus based splicing minigene plasmid.
Co-transfections ofminigene plasmids and plasmids encod-
ing defined recombinant proteins were performed as de-
scribed (17). The minigene inserts were PCR amplified with
primers (Forward) TCCTTCTGCCTTTGGCCCTA and
(Reverse) GAGGCTGGCATATGAAGGGG and cloned
onto the vector at theXbaI andXhoI cloning sites. RT-PCR
was done with common SP6 and T7 primers. To construct
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the single-intronminigene, the intron sequence between cas-
sette exon and downstream vector exon was completely re-
moved. The primers (Forward) TCCTTCTGCCTTTGGC
CCTA and (Reverse) CTTGAAAGAAAAAAAAAAAA
AGTGGATGGAATGGTGGAAGTwere used for IP-RT-
PCR analysis in Figure 4D.
RESULTS
CPs impact globally on cassette exon splicing
The impact of CPs on AS was assessed in K562 cells (46).
K562 is a Tier 1 ENCODE cell line that has served as an
intensively studied model of mammalian gene expression
and regulation of hematopoiesis. The workflow of the study
is outlined in Figure 1A. Three pools of K562 cells were
co-depleted of CP1 and CP2 via transfection with two
distinct siRNAs, each of which co-targeted conserved seg-
ments of the CP1 and CP2 mRNAs (‘CP1/2 siRNA’).
Three parallel cell pools were transfected with each of three
distinct control siRNAs (see Materials and Methods). Ef-
fective co-depletion of CP1/2 proteins was confirmed by
Western analysis (representative study; Figure 1B) and cor-
responding libraries were generated from RNAs isolated
from the three CP1/2 co-depleted pools and from each
of the three control pools. The six individually bar-coded
RNA-seq libraries were pooled and sequenced in a single
flow cell (Illumina Hiseq2000) to achieve a minimum depth
of 63 million reads per library (Supplementary Table S1).
The RNA-seq data were processed using rMATS (v3.0.7;
http://rnaseq-mats.sourceforge.net/, (39,40)) to detect dif-
ferential AS events triggered by CP1/2 depletion.
Co-depletion of CP1 and CP2 had a significant im-
pact on 1551 AS events in the K562 transcriptome. The
inclusion level of alternatively spliced exons was measured
as PSI (percent spliced in, or  ). The 1551 significant
AS events showed |PSI| ≥ 0.05 (at least 5% splicing
change upon CP1/2 depletion) and rMATS FDR < 5%.
The majority of the 1551 AS events comprised alterna-
tive inclusion/exclusion of cassette exons. There were 1051
skipped exon (SE) events involving 919 cassette exons (in
some cases, the cassette exons were involved in more than
one SE event) (Table 1A). The predominant event following
CP1/2 co-depletion was repression of cassette exon inclu-
sion: the inclusion of 749 exons was repressed in CP1/2-
depleted cells compared with 170 exons being enhanced.
These data lead us to conclude that CP1/2 have a wide
impact on splicing within the K562 transcriptome with a
predominant impact comprising the enhancement of cas-
sette exon inclusion.
Cassette exons enhanced by CP1/2 are selectively flanked
by C-rich motifs
The basis for the impact of CP1/2 co-depletion on cas-
sette exon splicing was assessed by motif enrichment anal-
ysis (MEME v4.9.0; see Materials and Methods). The tar-
get sequence field for this analysis comprised a 500 bp win-
dow centered on the splice acceptor or donor sites brack-
eting each of the 919 cassette exons impacted by CP1/2
co-depletion. These data were compared to a background
set of 4527 alternatively spliced exons in highly expressed
genes (FPKM > 5.0 in at least one sample) that were unaf-
fected by the CP1/2 depletion (rMATS FDR > 50%). To
filter out the those AS events that are almost always skipped
or almost always included, the exons in the background
set were required to be included at a frequency of >15%
in at least one condition (max (PSI-CP-KD, PSI-CTRL)
>15%) (removing exons almost always skipped) and less
than 85% in at least one condition (min (PSI-CP-KD, PSI-
CTRL) <85%) (removing exons almost always included).
The positional enrichment of identified motifs in the
vicinity of the CP impacted exons were determined by
examining the 500 bp windows in 50 bp bins with step-
size of 1 bp and determining the occurrence of each motif
within each bin.MEMEanalysis of the 749 CPs-enhanced
exons revealed a marked enrichment for a C-rich mo-
tif ([C/U][C/U][C/U][C/U]C[U/A][C/G]CC[C/U]) (Fig-
ure 1C, boxed sequence). Thismotif was highly enriched im-
mediately adjacent (5′ and/or 3′) to the exons whose splic-
ing was repressed in CP1/2 co-depleted cells (Figure 1C,
red line) and was specifically lacking in the 170 exons whose
splicing was increased in CP1/2 co-depleted cells (Figure
1C, blue line) and in the background exon set (Figure 1C,
black line) as well as within the exonic regions (Figure 1C,
green rectangle). In clear contrast, the MEME analyses re-
vealed that the two later groups of exons were preceded by
canonical U-rich polypyrimidine tract (Figure 1D, boxed
sequence) that is present at the majority of mammalian
splice acceptor sites and recognized by the PPTbinding pro-
tein, U2AF65 (Figure 1D, (8)).
MEME analysis was repeated using exon sets that con-
formed to a higher |PSI| (≥15%). With this more strin-
gent cutoff, there were 362 CPs-enhanced cassette ex-
ons, 56 CPs-repressed exons and 4742 background exons.
TheMEME analysis of these exons (Supplementary Figure
S1) revealed the same enrichment of a C-rich motif in the
CP1/2 enhanced exon set versus the U-rich motif in the
repressed and background exon sets as observed using the
|PSI| ≥ 0.05 cutoff. These results lead us to conclude that
CPs selectively enhance inclusion of a subset of cassette
exons by binding to an adjacent C-rich sequences overlap-
ping PPT sites. This linkage ofCP functionwith the C-rich
PPT is fully consistent with the binding specificity of CPs
for C-rich polypyrimidine motifs as defined in both in vitro
and in vivo settings (47).
The MEME analysis revealed that, of the 749 CP1/2-
enhanced exons, 92% (686) contained a C-rich intronic mo-
tif adjacent to either 5′or 3′ splice site whereas 63 lacked
this motif. Of the 686 exons containing C-rich flanking se-
quences, 94% (644) contained the C-rich motif upstream to
the target exon and in 44% (333) this C-rich motif was re-
stricted to this region (i.e. not present 3′ to the exon). In
contrast, only 6% (42) had the C-rich motif restricted 3′ to
the CP-enhanced exon (Table 1B). Chi-square analysis of
the co-occurrence frequencies of C-rich motifs both 5′ and
3′ to the 749 positively regulated exons, while numerically
apparent, did not reach statistical significance (chi-squared
= 2.17; P-value = 0.141). We conclude from these obser-
vations that the great majority of CP1/2 enhanced exons
contain aC-rich sequence thatmaps 5′ of the adjacent splice
acceptor.
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Prior studies from our laboratory and others have
identified an array of nuclear and cytoplasmic post-
transcriptional controls over critical cell functions that are
mediated by CPs. These include cell cycle control (48,49),
epithelial to mesenchymal transition (EMT) (27,50–55) and
cancer biology (32,50,56–58). With these findings in mind,
we performed Ingenuity pathway analysis to determine if
CP1/2 enhanced cassette exons were enriched in specific
cellular pathways or biological functions. Ingenuity anal-
ysis of the gene set containing CPs-impacted exons (Ta-
ble 2A) or the subset of CP-enhanced exons (Table 2B)
revealed enrichment in pathways related to cell death and
survival, cellular growth and proliferation, cell cycle con-
trols andRNApost-transcriptionalmodifications (Table 2).
These data support a link between the impact of CPs on
cassette exon splicing and defined roles of the CPs in fun-
damental cellular functions and disease processes.
Three cassette exons containing combinations of intronic
C-rich motifs located upstream and/or downstream of the
enhanced exon was next validated for CP dependence by
targeted RT-PCR (Figure 2A, B and C). Exon 5 of CDK2
is flanked both upstream and downstream by C-rich motifs,
exon 9 of SH2B1 has a C-rich PPT limited to its splice ac-
ceptor site, and exon 14 of TARS2 has a C-rich motif that
is limited to the splice acceptor site and is situated adjacent
to a short U-rich polypyrimidine segment. Eight additional
targeted validations of CP1/2-enhanced exons are shown
in Supplementary Figure S2. In all cases, the repression of
cassette exon inclusion in CP1/2-depleted cells was con-
firmed by the targeted analyses. These data lead us to con-
clude that the positive regulatory impact (enhancement) of
CPs on cassette exon splicing is mediated via CP binding
to corresponding C-rich motifs.
The twomajorCP isoforms,CP1 andCP2, individually
contribute to enhanced cassette exon splicing
The preceding data demonstrate that co-depletion of CP1
and CP2 enhances the splicing of a subset of cassette ex-
ons preceded by C-rich motifs. While CP1 and CP2 are
known to share a strong binding preference for C-rich mo-
tifs and to have extensive functional overlap, they have also
been shown to exert a subset of non-redundant functions
(28,59–61). We therefore sought to determine whether en-
hancement of C-rich motif activity was shared by the in-
dividual CP1 and CP2 isoforms. K562 cells were selec-
tively depleted of either CP1 or CP2 using in each case
three distinct sets of siRNAs (siRNAs CP1–1, 2 and 3, and
siRNAsCP2–1, 2 and 3). Parallel transfections were carried
out with siRNAs that co-deplete CP1 + CP2 (CP1/2–
1 and CP1/2–2) and with non-targeting control siRNAs
(see Materials and Methods). The isoform-specific deple-
tions were confirmed by Western analyses (Figure 3A) and
their impacts were assessed on the splicing of two exons
that are repressed in cells co-depleted for CP1/2: CTTN
(exon 11) and TARS2 (exon14) (Figure 3B). We observed
strong and equivalent levels of repression of CTTN (exon
11) in cells individually depleted of either CP1 or CP2
(Figure 3B) and the combined depletion of both isoforms
had an additive impact. For TARS2 (exon 14), the situation
was somewhat different in that CP1 depletion robustly re-
pressed cassette exon splicing while CP2 depletion had no
appreciable effect. In this case the combined depletion of
CP1 and CP2 was approximately equivalent to that of
CP1 alone. These data lead us to conclude that the two
major CP isoforms, CP1 and CP2, can each enhance
the splicing of a subset of exons although in certain set-
tings this impact can be isoform specific. The basis for this
isoform specificity for the enhancement of certain cassette
exon(s) remains unclear and will be the focus of subsequent
studies.
The link betweenCP function and enhancement of exon
splicing was further tested by CP depletion/repletion.
CP1/2 were co-depleted in K562 cells co-transfected with
a plasmid expressing Flag-tagged CP1 from shRNA ‘im-
mune’ mRNAs (seeMaterials andMethods). The depletion
of endogenous CP1 and the expression of the recombi-
nant CP1 protein were both confirmed by Western anal-
ysis of the respective co-transfected cells (Figure 3C). Anal-
yses of the CP1/2 depleted/repleted cells confirmed re-
pression of splicing of CTTN(exon 11) and of TARS2(exon
14) and demonstrated a partial reversal of this repression
in the presence of recombinant CP1 (Figure 3D). These
depletion/repletion studies further support the role ofCPs
in enhancing the splicing of cassette exons flanked by C-rich
sequences.
Minigene analyses confirm the essential roles of CPs and
the C-rich poly-pyrimidine tract in enhancement of cassette
exon splicing
The relationship of the C-rich PPTs and CP activity to the
control of cassette exon splicing was specifically tested in a
series of minigene splicing assays. The alternatively spliced
exon 14 of the TARS2 transcript along with its flanking in-
tronic sequences was assembled within an alternative splic-
ing minigene vector (Figure 4A). This TARS2 (exon 14)
minigene was transfected into K562 cells along with a plas-
mid expressing either an shRNA co-targeting CP1/2 ex-
pression or a scrambled shRNA. RT-PCR analysis three
days post-transfection revealed that CP1/2 co-depletion
repressed TARS2 (exon 14) splicing (Figure 4B). This re-
sponse parallels the impact of the CP1/2 co-depletion on
the native TARS2 transcript (Figure 3B), although the de-
gree of impact was less marked in the minigene context.
We next assessed the contribution of the C-rich motifs
5′ to the TARS2 exon 14 splice acceptor to splicing activ-
ity by introducing a stepwise reduction in the C/U ratio
within the PPT 5′ to exon 14 (Figure 4A, Muts 1 and 2).
RNA EMSAs confirmed that C → U substitutions within
the PPT resulted in the expected loss of CP binding (Fig-
ure 4C). Minigene splicing analysis revealed that the step-
wise C to U conversion (WT → Mut1 → Mut2) resulted
in a parallel step-wise increase in exon inclusion (34% →
61% → 94%, respectively). Importantly, these C→ U sub-
stitutions resulted in a progressive loss of splicing inhibition
subsequent toCP1/2 co-depletion (Figure 4B). These data
support the conclusion that the positive impact of CP1/2
on exon splicing is dependent on the presence of the C-rich
PPT. These data further suggest that the canonical U-rich
PPT has a stronger intrinsic splicing activity than the C-
rich PPT. This increase in the strength of the TARS2 (exon
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Figure 2. Targeted validations of CP-dependent cassette exon splicing. (A) Inclusion of CDK2 exon 5 is enhanced by CP1/2. Top: Genome browser
screenshot of CDK2 RNA-seq data from CP1/2 depleted cells (brown) and parallel scrambled siRNA-transfected controls (CTRL; green). The cassette
exon 5 is enclosed in the dotted box. The blue diagram represents gene structure; exons are shown as boxes and introns as dotted lines. The sequences
surrounding the cassette exon impacted by CP1/2 (exon 5) are shown in an expanded view: exonic sequence (blue uppercase), intronic sequences (lower
case) and C-rich regions (red font). The acceptor (ag) and donor (gt) dinucleotides are shown in bold. Bottom left: Diagram of the CDK2 transcript: the
impacted cassette exon (green) and the amplimer primers used for targeted analysis (forward and reverse; F and R) are shown below neighboring exons,
respectively. The RT/PCR validation study is shown in the adjacent gel; the numbers in the boxes indicate exon number. The cassette exon ‘Inclusion%’
was calculated as the ratio of exon included isoform over the sum of exon-included and exon-excluded isoforms derived from the analysis of two biologic
replicates. CTRL-1 and CTRL-2 represent different control siRNAs targeting an unrelated mRNA (GLD-2); CP(1/2)-1 and -2 are two different siRNAs,
each of which co-targets CP1 and CP2.P-value is shown below the gel. (B) Inclusion of SH2B1 exon 9. Data are organized as in (A), above. (C) Inclusion
of TARS2 exon 14. Data are organized as in (A) above.
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Figure 3. Each of the two major CP isoforms, CP1 and CP2, can individually enhance inclusion of cassette exons flanked by a C-rich splice acceptor
site. (A) Isotype-specific depletion of CP1 and CP2 proteins. K562 cells were individually transfected with three distinct siRNAs that selectively target
CP1 (CP1–1, CP1–2, CP1–3), or CP2 (CP2–1, CP2–2, CP2–3), or siRNAs co-targeting both CP isoforms (CP1/2–1, CP1/2–2, triplicate transfections
for each siRNA) as well as one siRNA control (triplicate transfections). The cells were assayed three days post transfection by Western blot with isotype-
specific antiseras as indicated to the left of each respective panel. Detection of the ribosomal protein, L7a, served as a loading control. The amount of
the remaining protein was calculated by comparing with control siRNA knockdown and adjusted to loading control L7a using Odyssey CLx Imaging
platform. (B) Impact of isotype-specific CP depletions on cassette exon splicing. Splicing analysis of two cassette exons flanked by C-rich motifs; TARS2
and CTTN. The organization of the figure is as described in Figure 2. The exon inclusion levels (%) in the presence of individual siRNAs to CP1, CP2 or
Control, are shown below each gel along with corresponding averages and significance values. *P< 0.05, **P< 0.01, ***P< 0.001. (C) Western analysis of
depletion-repletion assay. K562 cells were co-transfected with control or CP1/2 shRNAs as indicated, along with vectors expressing recombinant Flag-
tagged CP1 encoded by shRNA-immune mRNAs. V: empty vector; CP1: CP1 expression vector. Western assay of the cells 3 days post-transfection
confirmed the shRNA-mediated depletion and recombinant Flag-CP1 expression. (D) Repletion of CP1 partially restores exon splicing. Splicing levels
(Inclusion%) were assessed for CTTN and TARS2 by RT/PCR as described (Figure 3B). The averages and significance values were shown below each gel
(n = 4). *P < 0.05, ***P < 0.001. n.s., not significant.
14) splice acceptor subsequent to C→U replacement most
likely reflects an enhanced occupancy of U2AF65 at the
converted PPT. This was tested by a U2AF65 RNP co-IP in
cells expressing a single intron minigene carrying the 5′ ter-
minus and adjacent PPT of the TARS2(exon 14). The study
revealed an enrichment for the Mut-2 TARS2 pre-mRNA
in the U2AF65 IP’ed pellet when compared with the WT
counterpart (Figure 4D). These data support themodel that
AS regulation of cassette exons that are preceded by C-rich
PPTs bound by CPs is distinct from splicing control medi-
ated by U2AF65 binding to the canonical U-rich PPT.
Interactions ofCPs and U2AF65 in control of cassette exon
splicing
To further distinguish the functions of the CPs from
U2AF65, we assessed the impact of U2AF65 depletion on
splicing of CP-enhanced cassette exons. K562 cells were
depleted of U2AF65 using three distinct siRNAs with de-
pletion documented by Western analysis (Figure 5A). As
an initial set of positive controls, we assessed the impact
of the U2AF65 depletion on four cassette exons which are
validated as U2AF65-dependent (13); THYN1 (exon 7),
CAST(exon 8), EIF4A2(exon 11) and GSK3B(exon 9). The
result demonstrated that the splicing of these four exons
was either significantly inhibited (THYN1 and CAST) or
enhanced (EIF4A2 and GSK3B) in K562 cells depleted of
U2AF65 (Figure 5B and Supplementary Figure S3), con-
sistent with the original report (13). However, these four ex-
ons were either unaffected or slightly changed by CP1/2
co-depletion (Figure 5B and Supplementary Figure S3). A
reciprocal response profile was observed in the splicing ac-
tivities of a set of CP impacted cassette exons identified
in the current study; splicing was repressed in CP1/2 co-
depleted cells while there was no significant impact subse-
quent to U2AF65 depletion (Figure 5C and Supplementary
Figure S4). These data support the model in which C-rich
and U-rich sequences at PPTs are respectively regulated by
two distinct RNA binding proteins, CPs and U2AF65.
CP isoforms associate in vivo with critical splicing factors
The ability of CPs to enhance splicing through C-rich mo-
tifs at PPT site predicts that they recruit splicing factor(s)
that are involved in activation of the splicing pathway. Pro-
tein interaction networks suggest that CPs are involved in
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Figure 4. Minigene analysis confirms the impact of C-rich PPT on cassette exons splicing. (A) Diagram of TARS2 exon 14 mini-gene. The TARS2 exon
14 (light green rectangle) along with its contiguous intron sequence (red line) was inserted into a minigene test vector containing 5′ and 3′ exons (dark
green rectangles) with functional splice donor and splice acceptor sites, respectively. The forward (F) and reverse (R) primers used for the splicing analysis
are shown. The C-rich domains in the TARS2 exon14 segment are shown in red and the corresponding sequence substitutions are shown in blue. Intronic
sequences in lower case and the acceptor dinucleotide, ag, is bolded. Mutations were introduced into the upstream intron (Mut-1 and Mut-2) to disrupt
the integrity of C-rich sequence. These C → U substitutions, Mut-1 and Mut-2 are shown below the WT sequences. Each set of mutations was inserted
into the minigene and assessed for its impact on splicing efficiency. (B) Mini-gene splicing assay. The WT minigene and each of the two mutant minigenes
were co-transfected into K562 cells along with CP1/2 shRNA or control shRNA. The splicing efficiency of exon 14 is assessed by RT-PCR after a 3-day
incubation. (C) Impacts of C→ U substitutions on CP complex formation at the PPT are verified by RNA–EMSA. Electrophoretic mobility shift assays
(EMSA) for WT,Mut-1, Mut-2 and C26 positive control are shown. The positions of the CP-RNA complex and that of the free RNA probe are indicated
to the left of the gel image. (D) Occupancy of U2AF65 at the PPT is enhanced by C → U substitutions. The WT and Mut-2 TARS2 exon 14 segments
were assembled in corresponding single-intron minigene constructs (top diagram, labeling as in (A)). The WT and Mutant minigenes were individually
transfected into K562 cells and cell extracts isolated one day post-transfection were immunoprecipitated with antibodies to U2AF65. Pre-immune serum
(PI) was used as IP control. The occupancy of U2AF65 at the splice acceptor was assessed by RT-PCR of the co-IP’ed RNA. RT-PCR of GAPDHmRNA
was used as background control. The ratio of TARS2/GAPDH was calculated with the WT set as 1.0.
spliceosome assembly via interaction with the subunit 2 of
the splicing factor 3b protein complex, SF3B2–145 (3). Se-
quence independent binding of the SF3A/SF3B complex 5′
to the branch site is critical to anchoring U2 snRNP to the
pre-mRNA and is required for the early stage splicing ‘A’
complex and the ‘E’ complex assembly (8). The association
of CPs with specific splicing factors was tested by co-IP
of CP isoforms fromRNase-treated K562 cellular extract.
Western analysis revealed thatCP1 andCP2 IP’ed pellets
were both enriched for SF3B2–145 (Figure 6A, top panel).
Of additional interest was the observation that both IP’ed
pellets were also enriched for U2AF65 (Figure 6A, bottom
panel). These data suggest that CPs’ enhancement of C-
rich PPTs is linked to the association of CPs with both U2
snRNP and U2AF65.
U2AF65 can be recruited to the C-rich PPTs of CP-
enhanced exons via both direct and indirect interactions
The association of CPs with U2AF65 (Figure 6A) sug-
gested that these proteins may co-occupy subsets of PPTs.
To further explore the relationship of CP with U2AF65,
we compared U2AF65 occupancy as mapped in K562 by
U2AF65 eCLIP (ENCODE project (62)) and the presence
of the U-rich U2AF65 consensus motif (TTTTT[C/T]C)
(12) and two closely related U-rich motifs identified by
Zagros (63) (Supplementary Figure S5). These compar-
isons focused on sites flanking CPs-enhanced cassette ex-
ons, sites flanking CPs-repressed cassette exons, and sites
flanking a background exon control set (all groups as de-
fined in our initial transcriptome analyses (Figure 1)). The
marked enrichment of the U2AF65 binding motif and
U2AF65 occupancy 5′ to the CP-repressed and back-
ground exons (Figure 6B; ‘Repressed’ and ‘Background’)
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Figure 5. Differential contributions of CPs andU2AF65 to AS regulation. (A) U2AF65 depletion in K562 cells. The indicated control siRNA (triplicates)
or 3 independent U2AF65 siRNAs were expressed in K562 cells and assayed 3 days post transfection by Western analysis. The amount of the remaining
protein was calculated by comparing with control siRNA knockdown and adjusted to loading control L7a using Odyssey CLx Imaging platform. (B)
The impacts of U2AF65 and CP1/2 co-depletion on the splicing of two U2AF65-dependent exons; THYN1(exon 7) and CAST(exon 8). Levels of exon
inclusion (%) and averages as determined by targeted RT/PCR are shown below the respective lanes. The analysis reveals negative impact on cassette exon
splicing that is specific to the U2AF65 depletion. (C) Impacts of selective U2AF65 and CP1/2 depletions on the splicing of two CP-sensitive cassette
exons; VKORC1(exon 2) and TRPT1(exon 7). RT-PCR analysis data and averages are shown below the respective lanes. The analysis reveals negative
impact on cassette exon splicing that is specific to the CP1/2 co-depletion.
is fully consistent with the canonical model of U-rich PPT
recognition by U2AF65 in the great majority of mam-
malian exons (13). In contrast, the U-rich U2AF65 bind-
ing site motif was markedly under-represented 5′ to the
CP-enhanced exons (Figure 6B; ‘Enhanced’). Despite this
clear under-representation of the U2AF65 consensus 5′
to the CP-enhanced exons, the occupancy by U2AF65
at these sites was only minimally diminished when com-
pared to the two other exon groups (Figure 6B; ‘Repressed’
and ‘Background’). The observed discordance between the
U2AF65 binding site mapping and the corresponding levels
of U2AF65 occupancy suggest that U2AF65 can associate
in an indirect fashion with a substantial fraction of C-rich
PPTs. Based on the co-IP study (Figure 6A) we propose that
this indirect association of U2AF65 at these sites may be
mediated by association with the bound CPs.
The mapping data (Figure 6B) reveals a minor popula-
tion of CP-enhanced PPTs contain U-rich motifs (Figure
6B; small peak in top left panel) and thus may be directly
bound by U2AF65. This observation suggests that a sub-
set of exons may be under the combined/cooperative con-
trol of CPs and U2AF65. This model was tested by as-
sessing the impact of combined depletion of U2AF65 and
CP1/2 on the splicing of TARS2(exon 14) (Figure 7A).
The PPT preceding this CP-enhanced exon contains a
U-rich segment adjacent (3′) to the defined C-rich motifs
(Figure 2C). TARS2(exon 14) splicing is repressed 50% by
CP1/2 co-depletion (Figure 3B) whereas selective deple-
tion of U2AF65 had a smaller but significant repressive ef-
fect (73% → 54%)(Figure 7B). Remarkably, the combined
depletion of both CP1/2 and U2AF65 resulted in a dra-
matic repression of exon inclusion (to 11.5%). The magni-
tude of this repression substantially exceeds either individ-
ual effect (Figure 7B). These data lead us to conclude that,
CPs and U2AF65, while capable of acting independently,
can also act in concert to control the alternative splicing of
a defined subset of cassette exons.
DISCUSSION
Controls impacting mammalian mRNA splicing occur pri-
marily at the initial stages of spliceosome assembly on a tar-
get transcript (3,8). While several steps can theoretically be
targeted for splicing regulation, current evidence points to
the binding of U2AF65 to the PPT as an important con-
trol point in this process (8), this association of U2AF65
and the PPT can be inhibited, altered or enhanced (11,15).
In addition to hnRNPC and PTB (see Introduction), addi-
tional RNA-binding proteins can impact on U2AF65 bind-
ing and/or function and further highlight the importance
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Figure 6. U2AF65 associates with PPTs of CP-enhanced exons in the absence of its cognate binding site. (A) Enrichments of SF3B2–145 and U2AF65
in CP1 and in CP2 co-immunoprecipitates. K562 cell extracts were prepared in the presence of RNase A and subjected to immunoprecipitation with
isotype-specific antisera to CP1 and CP2 in parallel with IP with preimmune serum (PI). Each immunoprecipitate was resolved by SDS-PAGE and then
probed (Western blot) with antibodies specific to two splicing factors; SF3B2 and U2AF65. (B) Discordance between the distributions of cognate U2AF65
binding sites and U2AF65 occupancy in the regions 5′ to CP-enhanced exons. K562 U2AF65 eCLIP reads (‘U2AF65 binding density’; blue curves) are
displayed upstream and downstream of the three groups of cassette exons; CPs-enhanced, CPs-repressed and a defined background set (as defined in
Figure 1C and D). The data reveal pronounced occupancy of U2AF65 upstream of all three groups (blue curves). The distribution of the corresponding
U2AF65 binding site motifs (TTTTT[C/T]C) (red curves) parallel the binding density 5′ to the repressed and background exons but are dramatically
under-represented 5′ to the CP-enhanced exons. These data suggest that U2AF65 may be recruited to C-rich PPTs upstream of CP-enhanced cassette
exons by an indirect mechanism.
Figure 7. CPs and U2AF65 can act jointly to enhance inclusion of a cassette exon preceded by a PPT containing adjacent U-rich and C-rich motifs.
(A) Impact of CP1/2 and U2AF65 co-depletion. K562 cells were transfected with three siRNA targeting U2AF65 (U2AF65–1, 2 and 3) or were co-
transfected with a U2AF65 siRNA along with siRNAs that co-target both CP isoforms (CP1/2–1, CP1/2–2). All studies were carried out in triplicate.
The cells were assayed three days post transfection by RT-PCR on the splicing analysis of TARS2 as described (Figure 3B). (B) Quantitative impacts of
CP1/2 depletion, U2AF65 depletion and CP1/2 + U2AF65 depletion on TARS2 (exon 14) splicing. CP1/2 depletion data are from Figure 3B (studies
in Figures 3B and 7A were carried out and analyzed entirely in parallel). Averages and SDs are indicated. *P < 0.05, **P < 0.01, ***P < 0.001.
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of PPT recognition and function on the splicing pathway
(3,8). Importantly, two recent genome-wide analyses indi-
cate that U2AF65 only binds to a subset of functional 3′
splice sites. These data suggests that protein factors in ad-
dition to U2AF65 can impact on the activity of splice ac-
ceptors flanking a substantial fraction of mammalian exons
(13,15). Thus divergences in PPT structure and correspond-
ing divergences in locally bound proteins can serve as a basis
for specific controls over individual subsets of exons in the
mammalian transcriptome.
In this report, we identify 749 cassette exons whose splic-
ing is positively impacted byCP1/2RNAbinding proteins
(Table 1). Analysis of this exon set reveals a marked enrich-
ment for C-rich motifs in their flanking intronic sequences
(Figure 1). The most significant site of this cytosine enrich-
ment maps to the PPT adjacent to the 5′ splice site of 644 of
the 749 CP1/2-enhanced exons. The demonstration that
CP1/2 interact with splicing factors associated with the
U2 snRNP complex, namely SF3B2 and U2AF65 (Figure
6A), further suggested that the binding of CPs to C-rich
PPTs enhance recruitment of the U2 snRNP and subse-
quent spliceosome assembly on the target transcript. The
binding specificity of CPs for C-rich sequences is specific
and of high affinity (47), consistent with their specific im-
pact on C-rich intronic sequences. This binding activity is
clearly distinct from the specificity of U2AF65 for U-rich
PPTs. The data in this report demonstrate independent ac-
tions of CPs and U2AF65 in the respective control of C-
rich and U-rich subsets of PPTs (Figure 5). Thus we con-
clude that the involvement of CPs in splicing regulation
diverges from the canonical splicing model that relies on the
sole activity of U2AF65.
The in vivo association of both CP1 and CP2 with
U2AF65 (Figure 6A) and the discordance between themap-
ping of the U2AF65 binding site and U2AF65 occupancy
at PPT preceding CP enhanced exons (Figure 6B), is con-
sistent with a model in which CPs directly bound at the
C-rich PPTs facilitate indirect association/occupancy by
U2AF65. The data also reveal that a subset of C-rich PPTs
may exist in cis with U-rich PPTs, allowing for the coordi-
nated actions of bothU2AF65 andCPs (Figure 7). The ac-
tions of these two polypyrimidine-binding proteins is likely
to vary widely depending on the structures, sequences and
alignments of binding sites within intronic context with cor-
responding impacts on PPT activity and patterns of alter-
native splicing.
In summary, we conclude that CP proteins can enhance
the splicing of a defined subset of cassette exons by directly
binding to cytosine-rich PPTs and that this CP-controlled
pathway of post-transcriptional control is likely to play a
substantial role in the regulation of important cellular func-
tion. Genes impacted by CPs are enriched in basic cellular
functions involved in cell death and survival, cellular growth
and proliferation and cell cycle control (Table 2), consistent
with previously observed positive role of CPs on cell pro-
liferation (48). Most recently, our studies in mice have re-
vealed that germline inactivation of either of the two major
CP isoforms, CP1 or CP2, result in distinctly timed em-
bryonic lethality and that the specific loss ofCP2 has ama-
jor impact on differentiation of hematopoietic lineages (64).
The mechanisms underlying these phenotypes are likely to
reflect the splicing controls highlighted in this report and
support essential roles of CP proteins on alternative splic-
ing regulations critical to an array of development path-
ways.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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